TABLE 19-9.

Therapeutic Agents for Treating Gastric Ulcers in Foals

DRUG CATEGORY	DRUG	DOSE	ROUTE	FREQUENCY
Mucosal protectant	Sucralfate	10–20 mg/kg	p.o.	t.i.d. to q.i.d.
Histamine type 2 receptor antagonist	Cimetidine	10–20 mg/kg	p.o.	q4h
	Ranitidine	6.6 mg/kg	IV*	q4h
		5–10 mg/kg	p.o.	b.i.d. to q.i.d.
		0.8–2.2 mg/kg	IV	q.i.d.
Proton pump inhibitor	Omeprazole	4 mg/kg	p.o.	s.i.d.
		1–2 mg/kg	p.o.	s.i.d. (prophylaxis)
Antacids	Milk of Magnesia	2–4 oz	p.o.	s.i.d. to b.i.d.
	Maalox	240 ml	p.o.	q4h

^*IV, Intravenous.

Adapted from Barr B: Gastric ulcer prophylaxis in the critically ill equine neonate. In Wilkins PA, Palmer JE, editors: Recent advances in equine neonatal care, Ithaca, NY, 2001, International Veterinary Information Service (A0413.1101).

© 2004 International Veterinary Information Service

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.